WIXOM, Mich.—Rockwell Medical, a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, announced today that it has hired Raymond Pratt, MD, as chief medical officer.
Pratt will oversee the clinical development and FDA regulatory process for Rockwell's Soluble Ferric Pyrophosphate (SFP) and manage all aspects of clinical research and development for SFP and new drug indications.
Robert L. Chioini, chairman, CEO and president of Rockwell stated, "We are very pleased to have Dr. Pratt join Rockwell and lead our clinical team. Dr. Pratt has close to 20 years of drug development experience in all phases of the clinical development process and in multiple therapeutic areas, including nephrology. His experience and leadership will be invaluable to us as we go through the process of obtaining FDA market approval for SFP and other future indications. We look forward to the strategic contributions Dr. Pratt will make during this exciting time for Rockwell Medical."
Prior to joining Rockwell, Pratt worked at Shire Pharmaceutical Development from 2003-2010, as vice president R&D and the scientific leader in the Emerging Business Unit and Renal Business Unit. Previous roles at Shire included vice president Global Clinical Medicine and Global Clinical Affairs and head of U.S. Clinical Development.